NASDAQ:MLYS

Mineralys Therapeutics (MLYS) Stock Price, News & Analysis

Mineralys Therapeutics logo
$13.66 -0.50 (-3.53%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$13.66 -0.01 (-0.04%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Mineralys Therapeutics Stock (NASDAQ:MLYS)

Advanced

Key Stats

Today's Range
$13.57
▼
$14.79
50-Day Range
$13.66
▼
$29.40
52-Week Range
$13.57
▼
$44.13
Volume
1.35 million shs
Average Volume
2.06 million shs
Market Capitalization
$1.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.60
Consensus Rating
Hold

Company Overview

Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular and kidney conditions associated with excess aldosterone. The company is based in Radnor, Pennsylvania, and was founded in 2019.

Its lead product candidate, lorundrostat, is an investigational oral inhibitor of aldosterone synthase. Mineralys is studying the drug as a potential treatment for difficult-to-control hypertension and conditions related to excess aldosterone; it is not an approved or marketed therapy.

The company’s work is focused on drug development and clinical research, with trials primarily conducted in the United States. Jon Congleton serves as Mineralys Therapeutics’ chief executive officer.

AI Generated. May Contain Errors.

Mineralys Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

MLYS MarketRank™: 
2.533977861845 of 5 stars

Mineralys Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 471st out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mineralys Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    Mineralys Therapeutics has a consensus price target of $43.60, representing about 219.2% upside from its current price of $13.66.

  • Amount of Analyst Coverage

    Mineralys Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Mineralys Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Mineralys Therapeutics are expected to grow in the coming year, from ($4.64) to ($2.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mineralys Therapeutics is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mineralys Therapeutics is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Mineralys Therapeutics has a P/B Ratio of 2.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.71% of the float of Mineralys Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mineralys Therapeutics has a short interest ratio ("days to cover") of 4.95.
  • Change versus previous month

    Short interest in Mineralys Therapeutics has recently increased by 3.35%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Mineralys Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Mineralys Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Mineralys Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Mineralys Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    Only 2 people have searched for MLYS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mineralys Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,209,856.00 in company stock.

  • Percentage Held by Insiders

    18.94% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Mineralys Therapeutics' insider trading history.
Receive MLYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MLYS Stock News Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
Mineralys Therapeutics, Inc. (MLYS) Gets a Hold from UBS
See More Headlines

MLYS Stock Analysis - Frequently Asked Questions

Mineralys Therapeutics' stock was trading at $36.29 at the beginning of the year. Since then, MLYS stock has decreased by 62.4% and is now trading at $13.66.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released its earnings results on Wednesday, November, 4th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.55) by $0.09.
Read the conference call transcript
.

Mineralys Therapeutics (MLYS) raised $180 million in an IPO on Wednesday, February 8th 2023. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share.

Mineralys Therapeutics' top institutional shareholders include Catalys Pacific LLC (8.82%), State Street Corp (3.25%), Pictet Asset Management Holding SA (1.56%) and American Century Companies Inc. (1.44%). Insiders that own company stock include Brian Taylor Slingsby, Ra Capital Management, LP, Samsara Biocapital Gp, Llc, Srinivas Akkaraju, Jon Congleton, David Malcom Rodman, Eric Warren, Adam Scott Levy, Daphne Karydas and Alexander M Gold.
View institutional ownership trends
.

Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mineralys Therapeutics investors own include Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Tesla (TSLA), Amprius Technologies (AMPX), Aldeyra Therapeutics (ALDX), Amgen (AMGN) and Biogen (BIIB).

Company Calendar

Last Earnings
11/04/2026
Today
11/22/2026
9th Annual Evercore ISI HealthCONx Conference
12/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MLYS
CIK
1933414
Fax
N/A
Employees
76
Year Founded
2019

Price Target and Rating

High Price Target
$56.00
Low Price Target
$29.00
Potential Upside/Downside
+219.2%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$154.65 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-63.26%
Return on Assets
-56.64%

Debt

Debt-to-Equity Ratio
0.15
Current Ratio
11.83
Quick Ratio
11.83

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.69 per share
Price / Book
2.40

Miscellaneous

Outstanding Shares
88,560,000
Free Float
71,784,000
Market Cap
$1.21 billion
Optionable
Optionable
Beta
0.83

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:MLYS) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners